Mobile Logo

EdR Fund Global Healthcare Thematic equities

Thematic equities
Change in NAV (16/10/2017)
319.64 EUR
Adeline  SALAT-BAROUX–LU1160356694–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160356694–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
319.64 EUR
Change in NAV (16/10/2017)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (16/10/2017)
319.64 EUR
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 29/09/2017

The fund posted a gain in September, driven by the rebound that major pharmaceutical groups such as Pfizer and Bristol-Myers have seen, as well as mutual health insurers, while biotech stocks tended to mark time after recording a good start to the year. In the United States, a new Republican attempt to reform Obamacare has failed, and Congress now seems to be preoccupied by its tax reform plans. The biggest contribution comes from the US health mutual, Centene. Its stock reacted positively following its announcement of the takeover of Fidelis Care, the biggest Medicaid actor in the state of New York. In similar vein, China's 3SBio recorded strong growth after its acquisition of Therapure Biopharma, a Canadian company specialising in organic product manufacturing. There were some movements in the fund as we sold Vertex, given the valuation reached by its stock, and we took our profits on Humana health insurance. The position on Astrazeneca was strengthened in the wake of its very positive reporting on two Phase III clinical studies. These results significantly increase Tagrisso's sales prospects, for use in targeted therapies against cancer, and Durvalumab in immunotherapy. Meanwhile, we also strengthened our position on Tesaro. Its Zejula PARP inhibitor, already marketed in the United States, is expected to be approved in Europe. This treatment for ovarian cancer could also be prescribed in maintenance therapy, and is now the subject of new studies with other therapeutic indications.

View more View less

Change in NAV

Chart – Base 100 (16/10/2017)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates


Performance R-EUR Cumulative Annualised
Since 01/01/2017

3.80 %

6.95 %

3.80 %

6.95 %

1 Year

8.03 %

9.34 %

7.98 %

9.29 %

3 Year

34.41 %

41.68 %

10.35 %

12.30 %

5 year

89.73 %

106.06 %

13.66 %

15.55 %

Since inception

219.64 %

235.51 %

14.35 %

14.99 %

Since 01/01/2017 1 Year 3 Year 5 year Since inception
Cumulative

Share class (R-EUR)

Benchmark

3.80 %

6.95 %

8.03 %

9.34 %

34.41 %

41.68 %

89.73 %

106.06 %

219.64 %

235.51 %

Annualised

Share class (R-EUR)

Benchmark

7.98 %

9.29 %

10.35 %

12.30 %

13.66 %

15.55 %

14.35 %

14.99 %

*Rolling periods

Annual performance



Statistics

VolatilityTracking ErrorCorrelation coefficientInformation ratioSharpe ratio
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*18.50 %14.16 %5.75 %0.97 %-0.17 %0.49 %
3 Year *16.36 %14.73 %4.05 %0.97 %-0.25 %0.62 %
Max. drawdownAlphaBeta
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*-9.99 %-0.04 %1.27 %
3 Year *-25.27 %-0.12 %1.08 %
Max. monthly gain Since inception13.74 %
Max. monthly loss Since inception-17.75 %
Share class R-EUR
Benchmark
1 Year* 3 Year * 1 Year* 3 Year *
Volatility 18.50 % 16.36 % 14.16 % 14.73 %
Tracking Error 5.75 % 4.05 %
Sharpe ratio 0.49 % 0.62 %
Alpha -0.04 % -0.12 %
Correlation coefficient 0.97 % 0.97 %
Information ratio -0.17 % -0.25 %
Max. monthly loss -17.75 %
Max. monthly gain 13.74 %
Max. drawdown -9.99 % -25.27 %
Beta 1.27 % 1.08 %

Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
17/02/2009
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
EUR
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
1 Share
ISIN Code
LU1160356694
AuM (fund)
480 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
2,100 %
Current management fee
2.100 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value
Subscription fee
3.00 % max
Performance fee
15,000 %

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top